Matthew T. Wiley - Mar 15, 2023 Form 4 Insider Report for BioXcel Therapeutics, Inc. (BTAI)

Role
CHIEF COMMERCIAL OFFICER
Signature
/s/ Javier Rodriguez, as Attorney-in-Fact for Matthew T. Wiley
Stock symbol
BTAI
Transactions as of
Mar 15, 2023
Transactions value $
$0
Form type
4
Date filed
3/16/2023, 05:58 PM
Previous filing
Jan 19, 2022
Next filing
Apr 8, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BTAI Restricted Stock Units Award $0 +12K $0.00 12K Mar 15, 2023 Common Stock 12K Direct F1, F2
transaction BTAI Stock Option (Right to Buy) Award $0 +36K $0.00 36K Mar 15, 2023 Common Stock 36K $19.60 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
F2 The RSUs will vest and settle as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of Restricted Stock Units at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates.
F3 The option vests and becomes exercisable as to 25% of the underlying shares on the first anniversary of March 15, 2023 and the remaining 75% of the underlying shares in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates.